Highlights Newsletter 4

This newsletter presents you the following key sessions:

1. Video-interview with Prof. Philippe Moreau about CASSIOPEIA: the first phase III study to demonstrate
    clinical benefit of daratumumab plus standard of care in transplant-eligible NDMM patients

2. Single-agent gilteritinib improves response and survival in relapsed/refractory FLT3-mutated AML patients

3. Combining obinutuzumab with DHAP induces MRD negativity in three quarters of untreated mantle cell
    lymphoma patients

4. Overcoming the ‘don’t eat me signal’ in patients with refractory lymphoma

5. Subcutaneous daratumumab is non-inferior to the intravenous drug formulation in patients with relapsed
    or refractory multiple myeloma